Monthly Prescribing Reference

Safety of Glycopyrrolate Via eFlow Nebulizer Closed System Evaluated in COPD

SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the innovative, proprietary eFlow nebulizer closed system. Developed by PARI Pharma, eFlow is a ...
Mena FN

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

(MENAFN- PR Newswire) STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization ...
Business Wire

Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) ...
PR Newswire

PARI Pharma's Investigational Closed eFlow Nebulizer System Used in Two Successful Phase 3 Clinical Studies Evaluating Sunovion's SUN-101 (glycopyrrolate) in People with ...

STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
FierceBiotech

Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congres

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, ...
Finanznachrichten

PARI Pharma's eFlow Technology device, LAMIRA, approved as the only nebulizer system to deliver Insmed's ARIKAYCE (amikacin liposome inhalation suspension)

- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
PE Hub

Elevation Pharma Inks $17 Million

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive ...
FiercePharma

FDA Approves Pulmozyme with eRapid Nebulizer; CF Patients See 2 - 3 Minute Treatment Times

RICHMOND, Va., Jan. 26, 2015 /PRNewswire/ -- The eRapid Nebulizer System (eRapid) from PARI has been approved as the first electronic nebulizer by the Food and Drug Administration to deliver Genentech ...
FiercePharma

Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with ...